The effect of increasing the Vitamin B12 status of Romney ewes on foetal liver Vitamin B12, milk Vitamin B12 and liver Vitamin B12 concentrations in suckling lambs

AIM: To determine the effect of increasing the Vitamin B12 status of the ewe on the Vitamin B12 supply to the suckling lamb. METHODS: The Vitamin B12 status of the ewe was increased during gestation and lactation by three injections of a long-acting preparation of Vitamin B12 microencapsulated in an organic acid polymer. The Vitamin B12 status of the ewes and suckling lambs was assessed from changes in serum and liver Vitamin B12 concentrations. RESULTS: Compared to untreated animals, serum and liver Vitamin B12 concentrations of the treated ewes were increased at least 70% during gestation. Foetal liver Vitamin B12 concentrations were increased 270%. Over the lactation, ewe serum and milk Vitamin B12 concentrations were increased at least 200% and 44%, respectively. The liver Vitamin B12 stores of the newborn lambs from Vitamin B12-treated ewes were depleted within 58 days. There were no significant differences in the serum Vitamin B12 concentrations of suckling lambs from Vitamin B12-treated and untreated ewes. CONCLUSION: Ewes with a high Vitamin B12 status will ensure an adequate supply of Vitamin B12 to their lambs for at least the first 30 days of life. CLINICAL SIGNIFICANCE: In flocks grazing Co-deficient pastures, treating ewes with a long-acting Vitamin B12 supplement at mating will prevent Vitamin B12 (Co) deficiency in ewes, as well as their lambs, until they can be treated at tailing at 4-6 weeks of age.     

An evaluation of the efficacy of injectable microencapsulated vitamin B12 in increasing and maintaining the serum and liver vitamin B12 concentrations of lambs

AIM: To develop a long-acting Vitamin B12 injection to prevent Co deficiency in sheep. METHODS: Formulations of microencapsulated Vitamin B12 in lactide-glycolide polymers were injected intramuscularly or subcutaneously into the anterior neck region of groups of 10 lambs and their efficacy determined from changes in serum and liver Vitamin B12 concentrations. RESULTS: The 95:5 lactide glycolide and the 100 lactide formulations containing more than 12.5% Vitamin B12 w/w significantly increased and maintained serum Vitamin B12 concentrations for at least 210 days as well as liver Vitamin B12 concentrations in treated lambs when compared with untreated controls. CONCLUSIONS: Injections of microencapsulated Vitamin B12 in lactide/glycolide copolymers are able to increase and maintain the Vitamin B12 status of lambs for at least 210 days. CLINICAL SIGNIFICANCE: Another option for the prevention of Co deficiency in sheep is now available using a long acting injectable Vitamin B12.     

The efficacy of a subcutaneous injection of soluble Vitamin B12 in lambs

AIMS: To assess the efficacy of a soluble Vitamin B12 injection in lambs by measuring changes in the serum and liver Vitamin B12 concentrations. METHODS: Thirty-six lambs were injected subcutaneously with 2 mg of soluble Vitamin B12 while another group of 36 served as untreated controls. Blood and liver biopsy samples for Vitamin B12 determinations were collected just before the injection and at days 1, 2, 5, 8, 16, 24, 30 and 45. RESULTS: The serum Vitamin B12 concentrations of the Vitamin B12 treated lambs increased rapidly compared to the untreated lambs. Concentrations peaked at day 2, decreased rapidly to day 8, and then decreased more slowly until day 24 when there were no longer differences between the groups. Liver Vitamin B12 concentrations of the Vitamin B12 treated lambs were significantly greater over days 8-24. CONCLUSION: A subcutaneous injection of 2 mg of soluble Vitamin B12 was effective in increasing and maintaining the Vitamin B12 status of lambs for about 24 days. CLINICAL SIGNIFICANCE: This Vitamin B12 product is only effective for preventing cobalt deficiency in lambs for about 4 weeks.     

Absence of a weight gain response to Vitamin B12 supplementation in weaned dairy heifers grazing pastures of marginal cobalt content

AIM: To obtain information on serum and liver vitamin B12 and urinary methylmalonic acid concentrations as diagnostic tests to predict a weight gain response to supplementation with vitamin B12 in young dairy cattle when grazing pasture of low cobalt content. Methodology. Forty dairy cattle (12 Friesian, 14 Friesian x Jersey and 14 Jersey) were allocated to two equal sized groups, treated and untreated, based on liveweight. At monthly intervals for 14 months, all animals were weighed, their serum and urine sampled, their liver biopsied and the pasture sampled from the paddocks they were grazing and going to graze. Serum and liver were assayed for vitamin B12 concentrations. For the first 5 months of the trial, urine was assayed for methylmalonic acid concentrations. Both washed and unwashed pasture samples were assayed for cobalt concentrations. RESULTS: No weight gain response occurred vitamin B12 supplementation in young growing cattle grazing pasture with a cobalt concentration of 0.04-0.06 mg/kg DM. For 5 months of the trial, liver vitamin B12 concentrations from untreated calves were in the range 75-220 nmol/kg and serum vitamin B12 concentrations were as low as 72 pmol/1. There was no associated growth response to supplementation. CONCLUSION: Further trials involving young cattle grazing pastures with cobalt concentrations less than 0.04 mg/kg DM are required to reliably determine liver and serum vitamin B12 concentrations at which growth responses to vitamin B12 or cobalt supplementation are likely under New Zealand pastoral grazing conditions.     

Absence of a weight gain response to Vitamin B12 supplementation in weaned dairy heifers grazing pastures of marginal cobalt content

Aim. To obtain information on serum and liver vitamin B₁₂ and urinary methylmalonic acid concentrations as diagnostic tests to predict a weight gain response to supplementation with vitamin B₁₂ in young dairy cattle when grazing pasture of low cobalt content.

Methodology. Forty dairy cattle (12 Friesian, 14 Friesian × Jersey and 14 Jersey) were allocated to two equal sized groups, treated and untreated, based on liveweight. At monthly intervals for 14 months, all animals were weighed, their serum and urine sampled, their liver biopsied and the pasture sampled from the paddocks they were grazing and going to graze. Serum and liver were assayed for Vitamin B₁₂ concentrations. For the first 5 months of the trial, urine was assayed for methylmalonic acid concentrations. Both washed and unwashed pasture samples were assayed for cobalt concentrations.

Results. No weight gain response occurred to Vitamin B₁₂ supplementation in young growing cattle grazing pasture with a cobalt concentration of 0.04-0.06 mg/kg DM. For 5 months of the trial, liver Vitamin B₁₂ concentrations from untreated calves were in the range 75-220 nmol/kg and serum vitamin B₁₂ concentrations were as low as 72 pmol/1. There was no associated growth response to supplementation.

Conclusion. Further trials involving young cattle grazing pastures with cobalt concentrations less than 0.04 mg/kg DM are required to reliably determine liver and serum Vitamin B₁₂ concentrations at which growth responses to Vitamin B₁₂ or cobalt supplementation are likely under New Zealand pastoral grazing conditions.     

Growth response to increasing doses of microencapsulated vitamin B12 and related changes in tissue vitamin B12 concentrations in cobalt-deficient lambs

AIM: To investigate growth response of cobalt deficient lambs to increasing doses of microencapsulated vitamin B12, and to measure associated changes in serum and liver vitamin B12 concentrations over 243 days. METHODS: From a flock grazing pastures that had low cobalt (Co) levels (about 0.06 mg Co/kg dry matter), 4-6-week-old lambs (n=137) were assigned to four groups and received either no treatment or a subcutaneous injection of 3.0, 4.5 or 6.0 mg of microencapsulated vitamin B12 on Day 1. At approximately monthly intervals, all lambs were weighed and blood samples were collected from a selection (n=10) of monitor animals, up to Day 243. Liver biopsies were also carried out on the monitor lambs (n=8) on Days 1, 124 and 215. RESULTS: The vitamin B12-treated lambs grew significantly faster (p<0.001) than untreated animals. Liveweights after 243 days were 28, 45, 45 and 47 kg for the untreated, 3.0, 4.5 and 6.0 mg vitamin B12-treated lambs, respectively. Of the initial group of untreated lambs, 68% had to be removed before the end of the trial because of substantial weight loss, but none of the treated animals were similarly afflicted. Serum vitamin B12 concentrations increased in all vitamin B12-treated lambs, reaching a peak at Day 25, and those of the 4.5 and 6.0 mg vitamin B12-treated lambs remained significantly higher (except at Day 124) than the untreated lambs to Day 187. However, at Day 124, but not Day 215, the liver vitamin B12 concentrations of treated lambs were two to three times higher than those of controls. CONCLUSIONS: The growth rates of Co deficient lambs were markedly improved by injection of 3.0, 4.5 or 6.0 mg of microencapsulated vitamin B12, and liveweights were maintained for at least 243 days. Serum vitamin B12 concentrations were related to this growth response; concentrations of <220 pmol vitamin B12/l were associated with a 95% probability that lambs were Co deficient and would thus respond to Co/vitamin B12 supplementation. Based on these data, the current New Zealand reference criteria for Co deficiency should be reviewed. CLINICAL SIGNIFICANCE: An injection of 3 mg microencapsulated vitamin B12 given to lambs at tailing will treat Co deficiency and will increase and maintain liveweights in a flock for up to 8 months.     

Dose response effects of long-acting injectable vitamin B12 plus selenium (Se) on the vitamin B12 and Se status of ewes and their lambs

AIM: To determine the effect of increasing doses of long-acting injectable vitamin B12 plus selenium (Se) given pre-mating on the vitamin B12 and Se status of ewes and their lambs from birth to weaning. METHODS: Four groups of 24 Poll Dorset ewes each were injected 4 weeks pre-mating with different doses of a long-acting vitamin B12 + Se product, containing 3 mg vitamin B12 and 12 mg Se per ml. The treatment groups received 5 ml (15 mg vitamin B12 + 60 mg Se), 4 ml (12 mg vitamin B12 + 48 mg Se), 3 ml (9 mg vitamin B12 + 36 mg Se), or no vitamin B12 or Se (control). Twelve of the twin-bearing ewes per group were selected for the study. Efficacy of the product was evaluated from changes in the concentrations of vitamin B12 in serum and liver, and of Se in blood, liver and milk in the ewes during gestation and lactation, and in their lambs from birth to weaning. Pasture samples in paddocks grazed by the ewes and lambs were collected at about 2-monthly intervals from 200-m transects. RESULTS: The flock was Se-deficient, as the mean initial concentration of Se in the blood of ewes was 182 (SE 20.3) nmol/L. Compared with untreated controls, all doses significantly (p < 0.01) increased concentrations of Se in the blood of ewes for at least 300 days. Selenium concentrations in milk were likewise increased throughout lactation, as were those in the blood and liver of lambs. The mean concentration of vitamin B12 in the serum of ewes was initially > 1,000 pmol/L, but this decreased within 28 days to < 460 pmol/L. Treatment with the 5-ml and 4-ml doses raised serum vitamin B12 concentrations of ewes for at least 176 days (p < 0.01), while their lambs had significantly greater concentrations of vitamin B12 in serum and liver for less than 37 days after birth. Tissue concentrations and duration of elevation of both vitamin B12 and Se were proportional to the dose administered. The mean concentrations of Se and cobalt (Co) in the pastures were 32 and 74 microg/kg dry matter (DM), respectively. CONCLUSIONS: Injecting ewes from a Se-deficient flock 4 weeks prior to mating with 48 or 60 mg Se and 12 or 15 mg vitamin B12 increased and maintained the Se status of ewes for at least 300 days, and of their lambs from birth to weaning. The vitamin B12 status of ewes was increased for at least 176 days and that of their lambs for less than 37 days. Due to the proportional nature of the response to increasing dosage, the dose rate of the formulation tested can be adjusted according to the severity of Se and Co deficiency in a flock. CLINICAL SIGNIFICANCE: A single subcutaneous injection of vitamin B12 + Se administered pre-mating to Se-deficient flocks is likely to prevent Se deficiency in ewes and their lambs until weaning, as well as increase the vitamin B12 status of ewes and their lambs until 5 weeks after lambing.     

Growth response to increasing doses of microencapsulated vitamin B12 and related changes in tissue vitamin B12 concentrations in cobalt-de cient lambs

AIM: To investigate growth responses of cobalt-deficient lambs to increasing doses of microencapsulated vitamin B₁₂, and to measure associated changes in serum and liver vitamin B₁₂ concentrations over 243 days.

METHODS: From a flock grazing pastures that had low cobalt (Co) levels (about 0.06 mg Co/kg dry matter), 4-6-week-old lambs (n=137) were assigned to four groups and received either no treatment or a subcutaneous injection of 3.0, 4.5 or 6.0 mg of microencapsulated vitamin B₁₂ on Day 1. At approximately monthly intervals, all lambs were weighed and blood samples were collected from a selection (n=10) of monitor animals, up to Day 243. Liver biopsies were also carried out on the monitor lambs (n=8) on Days 1, 124 and 215.

RESULTS: The vitamin B₁₂-treated lambs grew significantly faster (p<0.001) than untreated animals. Liveweights after 243 days were 28, 45, 45 and 47 kg for the untreated, 3.0, 4.5 and 6.0 mg vitamin B₁₂-treated lambs, respectively. Of the initial group of untreated lambs, 68% had to be removed before the end of the trial because of substantial weight loss, but none of the treated animals were similarly afflicted. Serum vitamin B₁₂ concentrations increased in all vitamin B₁₂-treated lambs, reaching a peak at Day 25, and those of the 4.5 and 6.0 mg vitamin B₁₂-treated lambs remained significantly higher (except at Day 124) than the untreated lambs to Day 187. However, at Day 124, but not Day 215, the liver vitamin B₁₂ concentrations of treated lambs were two to three times higher than those of controls.

CONCLUSIONS: The growth rates of Co-deficient lambs were markedly improved by injection of 3.0, 4.5 or 6.0 mg of microencapsulated vitamin B₁₂, and liveweights were maintained for at least 243 days. Serum vitamin B₁₂ concentrations were related to this growth response; concentrations of <220 pmol vitamin B₁₂/l were associated with a 95% probability that lambs were Co-deficient and would thus respond to Co/vitamin B₁₂ supplementation. Based on these data, the current New Zealand reference criteria for Co deficiency should be reviewed.

CLINICAL SIGNIFICANCE: An injection of 3 mg microencapsulated vitamin B₁₂2 given to lambs at tailing will treat Co deficiency and will increase and maintain liveweights in a flock for up to 8 months.     

Vitamin B12 and monensin effects on performance, liver and serum vitamin B12 concentrations and activity of propionate metabolizing hepatic enzymes in feedlot lambs

Monensin in ruminant diets increases production of propionic acid. We have tested the hypothesis that propionic acid may be elevated to such an extent by monensin that it cannot be optimally metabolized by the methyl malonyl-CoA pathway requiring vitamin B12 (B12) in the liver. Thus, the effects of weekly B12 injections (10 mg X head-1 X wk-1, intramuscularly) with and without dietary monensin (25 mg/kg diet) on average daily gain (ADG), dry matter intake (DMI), feed to gain ration (F/G), liver and serum B12 concentrations and liver activity of propionate metabolizing enzymes were examined in an 84-d trial. Sixteen lambs (27.5 kg average initial wt) were assigned randomly to one of four treatments in a factorial arrangement: monensin plus B12, monensin without B12, no monensin plus B12 and no monensin without B12. Lambs were fed an 80% concentrate diet and slaughtered at the end of the trial. Liver samples were obtained by biopsy on d 0 and at slaughter on d 84 to determine activity of propionate metabolizing enzymes and B12 concentrations. Serum samples were taken on d 0, 28, 56 and 84 to determine serum B12 concentration. Neither monensin nor B12 affected (P greater than .10) ADG, DMI or F/G. Lambs receiving B12 had higher (P less than .01) serum B12 concentrations, but this was not reflected (P greater than .10) in higher liver B12 concentrations. No difference (P greater than .10) in liver propionate metabolizing activity among treatments was detected; however, monensin decreased (P less than .05) fumarate and malate formation by liver homogenates. Liver B12 concentrations were highly correlated with endogenous propionate metabolizing activity at d 0 (r = .73, P less than .01) and d 84 (r = .51, P less than .05). Results suggest no advantage to providing supplemental B12 to lambs fed monensin-supplemented, high-concentrate diets.     

Thyroid hormones and metabolic rate during induction of Vitamin B12 deficiency in goats

Vitamin B12 deficiency was induced in 15 small East African goats by feeding cobalt deficient Chloris gayana hay (containing 0.02 mg of Co/kg dry matter) over a 25 week experimental period. Cobalt was supplemented as an oral drench to supply 0.3 g of Co/goat/week to 15 treated goats. At intervals of 3-4 weeks, serum concentrations of Vitamin B12 , total thyroxine (TT4), free tetra-iodothyronine (FT4) and free tri-iodothyronine (FT3) were determined by radioimmunoassay, while the rate of resting metabolism was determined by measuring the goats' rate of oxygen consumption. Serum Vitamin B12 concentration was significantly higher (p<0.01) in cobalt-treated (289.6 +/- 40.76 pg/ml) than in control (142.8 +/- 28.27 pg/ml) goats. The mean serum TT4 concentration was significantly (p<0.01) higher in control (59.0 +/- 1.70 nmol/l) than in cobalt-treated (51.6 +/- 2.45 nmol/l) goats. However, the levels of FT4, FT3 and the rate of resting metabolism were unaffected by the goats' cobalt status. Furthermore, the goats did not lose weight or become anaemic.     

Changes in serum concentrations of methylmalonic acid and vitamin B12 in cobalt-supplemented ewes and their lambs on two cobalt-deficient properties

AIM: To determine concurrent changes in serum methylmalonic acid (MMA) and vitamin B12 concentrations of ewes and their lambs on cobalt-deficient properties, subsequent to cobalt supplementation. METHODS: Three experiments were carried out on two farms. Groups of ewes (n=25-50) were either supplemented with cobalt bullets during late pregnancy, 23-47 days before the mean lambing date, or left unsupplemented. In two experiments, lambs from within each group were supplemented directly by vitamin B12 injection at 3-weekly intervals from birth, and in the third experiment by injection with micro-encapsulated vitamin B12 at tailing and 3 months later. Pasture samples were obtained for analysis of cobalt content at each sampling time. Blood samples were obtained and liveweight recorded from ewes and lambs at approximately monthly intervals. On one farm (two experiments), liver and milk samples were obtained from ewes and liver samples from lambs. RESULTS: Serum vitamin B12 concentrations in unsupplemented ewes fell below 250 pmol/L during early lactation in all experiments and mean concentrations as low as 100 pmol/L were recorded. MMA concentration was maintained below 2 micromol/L in serum from supplemented ewes but increased to mean concentrations ranging from 7 to 14 micromol/L at the nadir of serum vitamin B12 concentration during peak lactation. A significant liveweight response to supplementation was recorded in ewes on one property, and the vitamin B12 concentration in the ewes' milk and in the livers of their lambs more than doubled. No liveweight-gain response to supplementation was observed in lambs on this property. Mean serum MMA concentrations in lambs ranged from <2 in supplemented, to 19.2 micromol/L in unsupplemented lambs, and the latter had concurrent serum vitamin B12 concentrations of >300 pmol/L. Pasture cobalt concentration was lowest at 0.04-0.09 microg/kg dry matter (DM) on the property on which responses in lambs occurred but considerably higher (>0.09 microg/kg DM) on the property on which responses in ewes occurred. On the second property, serum vitamin B12 concentrations in lambs at tailing were extremely low (100 pmol/L), irrespective of supplementation of dams with cobalt. Mean serum MMA concentration was increased to 20 and 42 micromol/L in lambs from supplemented and non-supplemented ewes, respectively. Weight-gain response to direct supplementation of lambs with vitamin B12 occurred during suckling in the latter, but not the former. Lambs from ewes supplemented with vitamin B12 showed a much bigger increase in serum vitamin B12 concentrations a month after supplementation than did lambs from unsupplemented ewes (+1,400 pmol/L vs + 650 pmol/L). CONCLUSIONS: Serum MMA concentration gave a more precise indication of responsiveness to vitamin B12 or cobalt supplementation than serum vitamin B12 concentrations in ewes and lambs. Neither very low serum vitamin B12 nor elevated MMA concentrations were necessarily indicative of responsiveness to supplementation in suckling lambs, but the latter gave an early indication of impending responsiveness. Supplementation of the ewe with a cobalt bullet appeared to protect the growth performance of the lamb for 90 days and influence the subsequent serum vitamin B12 response in the lamb to vitamin B12 supplementation. CLINICAL SIGNIFICANCE: Supplementing ewes with cobalt bullets in late pregnancy can improve the vitamin B12 status of their lambs, and modify their response to vitamin B12 supplementation.     

The effect of long-acting injectable selenium formulations on blood and liver selenium concentrations and liveweights of red deer (Cervus elaphus)

AIM: To evaluate the efficacy of a new long acting injectable selenium ( Se ) formulation to increase the Se status and prevent Se deficiency in red deer. METHODS: Groups of weaned red deer (four stags and six hinds/group) grazing pastures containing <30 mg Se/kg DM were injected subcutaneously with either 0.5, 1.0 or 2.0 mg Se/kg as a new formulation of BaSeO4 (Deposel Multidose), 1.0mgSe/kg of a current formulation (Deposel), or not treated. Blood Se concentrations and liveweight were measured nine times at intervals over 377 and 270 days, respectively. RESULTS: Both formulations of Se elevated blood Se concentrations from 105 nmol/l pre-injection for at least 377 days with peak levels of 1894, 1395 and 818 nmol/l for high, medium and low doses of Deposel Multidose, respectively, at 73141 days, and 1508 nmol/l at 73-141 days for the medium dose of Deposel, which persisted at similar levels for the duration of the study. Deposel Multidose produced fewer and less severe subcutaneous tissue reactions than Deposel. Pastures contained 10 to 30 mg Se/kg DM. There was no significant difference in growth rate between treated and control deer. There was a significant (p<0. 01) linear relationship (y = 1.25x + 71.6, R2=0.86) between blood (x) and liver (y) Se concentrations in the range of 120 - 2100 nmol/l for blood concentrations, and 200 - 3000 nmol/kg for liver concentrations. CONCLUSION: Injections of BaSeO4 in both formulations studied were effective in increasing the Se status of deer but the new formulation produced fewer and less-severe tissue reactions. Young growing red deer appear less sensitive to Se deficiency as measured by weight gain, than sheep and cattle, suggesting that reference ranges for those species are not appropriate for deer. There was a linear correlation between blood and liver selenium concentrations.     

An assessment of the efficacy and safety of selenium and cobalt included in an anthelmintic for sheep

A trial was devised to assess whether the administration of selenium and cobalt together with the anthelmintic mebendazole (Ovitelmin S&C) was safe and could improve the supplies of selenium and cobalt for adult sheep fed a whole grain diet, low in both elements, which produced a steady decrease in blood glutathione peroxidase (GSHPx) and plasma vitamin B12 concentrations. Ovitelmin S&C, when given orally in a single dose as a suspension containing 0.34 mg selenium/ml, and 0.44 mg cobalt/ml (to provide 0.11 mg selenium and 0.15 mg cobalt/kg liveweight) significantly increased the GSHPx activity in blood. After a second dose given 28 days later the rate of change increased from 2.5 to 3.5 u/g haemoglobin/day. The responses in GSHPx were similar for a preparation which contained twice the concentration of selenium. Ovitelmin S&C increased the concentration of vitamin B12 in the plasma by about 1000 pg/ml for four to seven days after each dose and the increases were similar to those observed in sheep treated with an Ovitelmin preparation containing 45 times more cobalt (providing 6.7 mg cobalt/kg liveweight). After 63 days, liver vitamin B12 concentrations were 43 per cent higher in the cobalt treated than in the untreated groups (P less than 0.01) with no differences among the groups given cobalt. Neither adverse reactions nor signs of toxicity followed the administration of Ovitelmin S&C or Ovitelmin containing the higher concentrations of selenium and cobalt.     

The effect of sporidesmin toxicity on ovine serum vitamin B12 levels

A field outbreak of facial eczema occurred during a vitamin B12 response trial in young growing sheep. Pasture cobalt levels were in the low range for sheep (<0.08 mg/kg, 1.358 micromol/kg) and mean (of 3) liver vitamin B12 levels in the sheep were low (<400 nmol/kg) during the period in which facial eczema occurred. Mean serum vitamin B12 levels of the untreated group were low (<485 pmol/l) for the two months (January and February) preceding the period of facial eczema. However, levels showed an approximate 3.5 fold increase in both cobalt supplemented and unsupplemented groups with the onset of facial eczema in March. From February to March the mean serum vitamin B12 and glutamyl transferase (GGT) activity showed parallel increases with a positive correlation (r = 0.73) between log serum vitamin B12 and log serum GGT activity during the period January to July for both groups. This finding suggested that the increase in serum vitamin B12 was due to sporidesmin induced liver damage. The diagnostic implication is that, in areas where facial eczema is a problem, liver is the sample of choice for determining vitamin B12 status. because sporidesmin toxicity can elevate low serum vitamin B12 levels to diagnostically normal levels.     

Vitamin B12 supplementation and milk production on farms with 'chronic wasting' cattle

From early 1999 onwards, cattle health problems accompanied by chronic wasting of unknown aetiology were reported on a number of dairy farms. An association between these health problems and the compulsory use of gE-negative marker vaccines against bovine herpesvirus 1 was presumed by farmers. On one dairy farm an increased milk production of 50% was reported within a few days after parenteral vitamin B12 treatment. Therefore, the current study was designed to determine the effect of parenteral vitamin B12 treatment on the milk production of dairy herds with wasting cattle. A randomized blind trial was performed in five problem herds and two control herds. On each farm five lactating cows were injected intramuscularly with 20 mg vitamin B12 and paired with five untreated lactating cows. The milk production of treated and untreated animals was measured for 19 days following treatment and compared to pre-treatment production. No effect of vitamin B12 treatment on milk production was established on either problem farms or control farms. Neither was a difference detected in the response to vitamin B12 treatment between problem herds and control herds. In a second experiment, parenteral vitamin B12 treatment was applied in three problem herds by local veterinary practitioners. The results of this experiment were in line with the results of the first experiment.     

Impact of iodine supplementation of dairy cows on milk production and iodine concentrations in milk

AIM: To determine the effect of iodine supplementation on milk production and iodine concentrations in milk for pasture-fed, seasonally calving dairy cows. METHODS: The study was run over two consecutive seasons on the same dairy farm. In Trial One, 294 Friesian dairy cows were either untreated or injected intramuscularly three times with iodised oil (2,370 mg iodine/dose) at the start of lactation (Day 1) and at about 100-day intervals thereafter. Iodine concentrations in milk were determined prior to each injection on Days 1, 98 and 210, and milk, fat and protein yields measured on Days 43, 98, 176 and 238. In Trial Two, 234 Friesian dairy cows were either untreated or injected intramuscularly with iodised oil (2,370 mg iodine/dose) in early lactation (Day 1) and 99 days later. Iodine concentrations in milk were determined prior to treatment on Days 1, 55 and 161. Serum thyroxine (T4) and triiodothyronine (T3) concentrations were determined in the latter two samples and milk, protein and fat yields were determined on Days 25, 119, 182 and 221. In both trials, pasture was sampled at 1- or 3-monthly intervals and iodine concentrations in herbage measured. RESULTS: Iodine concentrations in pasture averaged 0.24 mg/kg dry matter (DM) in both seasons and varied little over the experimental period. Iodine concentrations in milk from unsupplemented cows were <20 microg/L in both trials. Three iodine injections at about 100-day intervals increased iodine concentrations in milk to 58 microg/L for at least 98 days after each treatment. Two iodine injections at about 100-day intervals raised milk iodine concentrations to 160 microg/L and 211 microg/L at least 55 days after each treatment, but had no effect on serum thyroid hormone concentrations. Iodine supplementation had no significant effect on milk, milkfat or milk protein yield. CONCLUSIONS: Pastures in New Zealand that contained 0.24 mg iodine/kg DM appeared to provide an adequate iodine intake for dairy cows. Intramuscular injections of iodine resulted in significant increases in iodine concentrations in milk. CLINICAL SIGNIFICANCE: Increasing iodine concentrations in milk via intramuscular injection of iodine could provide a method for significantly increasing iodine intakes of humans, in particular, children.     

维生素A、E对獭兔繁殖性能的影响

28只繁殖獭兔随机均分两组,基础日粮相同,试验组自配种前3天至妊娠第7天于日粮中添加维生素A8mg/kg、维生素E100mg/kg。结果与对照组相比:试验组产活仔数提高了20.23%(P<0.05),断奶成活率提高了7.23%(P<0.05),增重提高7.11%(P<0.05)。     

Efficacy of tilmicosin in treatment of pulmonary infections in calves.

The efficacy of tilmicosin in the treatment of respiratory infections in calves was evaluated. According to a randomised block design, 58 calves with naturally occurring respiratory infections were treated with one of the following products: a single subcutaneous injection of tilmicosin (10 mg/kg liveweight) or daily intramuscular injections of 5 mg lincomycin and 10 mg spectinomycin/kg liveweight, for a minimum of three days. Both treatment groups initially showed similar clinical signs and their initial responses to the treatments were good. However, the tilmicosin treated calves improved more rapidly. Significantly greater improvements (P less than or equal to 0.05) were observed in their demeanour and appetite during the first 10 days after treatment began, and in their respiratory condition between five and 10 days after treatment began.     

Thyroid hormones and metabolic rate during induction of Vitamin B12 deficiency in goats

Vitamin B₁₂ deficiency was induced in 15 small East African goats by feeding cobalt deficient ^{Chloris guyana} hay (containing 0.02 mg of Co/kg dry matter) over a 25week experimental period. Cobalt was supplemented as an oral drench to supply 0.3 g of Co/goat/week to 15 treated goats. At intervals of 3–4 weeks, serum concentrations of Vitamin B₁₂ total thyroxine (TT₄), free tetra-iodothyronine (FT₄) and free tri-iodothyronine (FT₃) were determined by radioimmunoassay, while the rate of resting metabolism was determined by measuring the goats' rate of oxygen consumption.

Serum Vitamin B₁₂ concentration was significantly higher (p<0.01) in cobalt-treated (289.6 ± 40.76 pg/ml) than in control (142.8 ± 28.27 pg/ml) goats. The mean serum TT₄ concentration was signifieantly (p<0.01) higher in control (59.0 ± 1.70 nmol/l) than in cobalt-treated (51.6 ± 2.45 nmol/l) goats. However, the levels of FT₄, FT₃ and the rate of resting metabolism were unaffected by the goats' cobalt status. Furthermore, the goats did not lose weight or become anaemic.     

钴和铜对肉用绵羊维生素B_(12)合成、瘤胃发酵及造血机能的影响

为研究不同水平的钴和铜对肉用绵羊维生素B12合成、瘤胃发酵及造血机能的影响,试验选20只体重相近(28.9±1.1)kg、装有永久瘤胃瘘管的杂交一代羯羊,随机均分为5组,定量饲喂对照组日粮,4种不同水平的钴铜(0.3:10、0.3:20、0.6:10和0.6:20)日粮。结果表明:瘤胃维生素B12合成主要取决于钴的摄入量,日粮中同时添加钴、铜及其不同的配比对维生素B12合成未显协同效应和影响。钴与铜合用可增加瘤胃挥发性脂肪酸的浓度,并改变乙酸、丙酸和丁酸比例,用量越多其影响越大。随肉羊日粮中钴与铜合用及其用量增加,可更有效地促进铁的吸收和利用,从而更加明显地改善机体的造血机能。